Compare FIHL & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FIHL | EVO |
|---|---|---|
| Founded | 2014 | 1993 |
| Country | Bermuda | Germany |
| Employees | N/A | 4553 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.1B |
| IPO Year | 2015 | N/A |
| Metric | FIHL | EVO |
|---|---|---|
| Price | $20.71 | $2.80 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 1 |
| Target Price | ★ $22.79 | $7.00 |
| AVG Volume (30 Days) | ★ 345.1K | 40.1K |
| Earning Date | 05-13-2026 | 04-08-2026 |
| Dividend Yield | ★ 2.87% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $15.94 | $1.37 |
| Revenue Next Year | $7.04 | $10.05 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.80 | $2.31 |
| 52 Week High | $21.50 | $4.42 |
| Indicator | FIHL | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 53.28 | 43.13 |
| Support Level | $17.93 | $2.63 |
| Resistance Level | $21.45 | $3.82 |
| Average True Range (ATR) | 0.49 | 0.07 |
| MACD | -0.07 | -0.00 |
| Stochastic Oscillator | 30.70 | 21.62 |
Fidelis Insurance Holdings Ltd is a specialty insurer that leverages strategic partnerships to offer tailored insurance solutions. The company classifies its business into two segments, Insurance and Reinsurance. A majority of its revenue is generated from the Insurance segment, which comprises a portfolio of property, marine, aviation and aerospace, political risk, violence and terror, energy, cyber, and other insurance risks. The Reinsurance segment consists of an actively managed property reinsurance book, providing reinsurance and a limited amount of retrocession coverage across the world on a proportional or excess-of-loss basis. Geographically, the company derives its key revenue from the United Kingdom, followed by Bermuda and the Republic of Ireland.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.